UNSPSC 51183619: Pramlintide

This classification denotes an anti-diabetic agent with the molecular formula C171H267N51O53S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) D3FM8FA78T, chemically known as l-tyrosinamide, l-lysyl-l-cysteinyl-l-asparaginyl-l-threonyl-l-alanyl-l-threonyl-l-cysteinyl-l-alanyl-l-threonyl-l-glutaminyl-l-arginyl-l-leucyl-l-alanyl-l-asparaginyl-l-phenylalanyl-l-leucyl-l-valyl-l-histidyl-l-seryl-l-seryl-l-asparaginyl-l-asparaginyl-l-phenylalanylglycyl-l-prolyl-l-isoleucyl-l-leucyl-l-prolyl-l-prolyl-l-threonyl-l-asparaginyl-l-valylglycyl-l-seryl-l-asparaginyl-l-threonyl-, cyclic (2-7)-disulfide but more generally known as pramlintide, which bears US NIH Compound Identifier 16132446.

UNSPSC 51183619 Pramlintide is a Commodity code covering a synthetic amylin analog pharmaceutical used to manage blood sugar in patients with diabetes. State and local governments procure this drug primarily through Medicaid programs, health department formularies, and public health clinics serving low-income and uninsured populations. The drug is typically sourced as a finished pharmaceutical product—supplied in injectable pen or vial form—rather than as a raw active pharmaceutical ingredient. Issuing bodies include state Medicaid agencies, county health departments, municipal health clinics, and independent health districts that operate community health centers and emergency services. Procurement under this code reflects the regulatory and clinical scope of state and local pharmacy benefit management, where formulary inclusion and reimbursement decisions drive demand.

The source provided contains no recent state or local contract opportunities tagged to this code, making it impossible to characterize current geographic activity, issuing-body concentration, or representative recent solicitations. This absence of posted opportunities may reflect the nature of pharmaceutical procurement at state and local levels—many jurisdictions source pramlintide through standing Medicaid vendor agreements, group purchasing organizations (GPOs), or prime vendor contracts rather than through advertised RFPs or IFBs. Firms pursuing this code should monitor Medicaid procurement portals and state health department solicitation channels, as activity may emerge through cooperative purchasing vehicles or direct-award mechanisms not typically visible in general procurement databases.